Eun Yang's Stock Ratings

Jefferies Analyst

Eun Yang is an analyst at Jefferies. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

-24.4%

Smart Score

37.1%

Overall Average Return Percentile

9th

Number of Ratings

20
Buy NowGet Alert
05/14/2024TSHABuy Now
Taysha Gene Therapies
$3.00167.11%$2 → $8AssumesHold → BuyGet Alert
04/29/2024DCPHBuy Now
Deciphera Pharmaceuticals
$25.480.47%$26 → $25.6DowngradeBuy → HoldGet Alert
03/25/2024ATXSBuy Now
Astria Therapeutics
$9.59181.54%$22 → $27MaintainsBuyGet Alert
03/25/2024AVTEBuy Now
Aerovate Therapeutics
$20.17222.26%$21 → $65AssumesBuy → BuyGet Alert
02/07/2024RLYBBuy Now
Rallybio
$1.61-6.83%$7 → $1.5DowngradeBuy → HoldGet Alert
12/15/2023RPHMBuy Now
Reneo Pharmaceuticals
$1.781.12%$17 → $1.8DowngradeBuy → HoldGet Alert
07/18/2023BBIOBuy Now
BridgeBio Pharma
$29.0913.44%$24 → $33DowngradeBuy → HoldGet Alert
06/26/2023BMEABuy Now
Biomea Fusion
$11.76138.1%$36 → $28DowngradeBuy → HoldGet Alert
03/29/2023ELVNBuy Now
Enliven Therapeutics
$24.0012.5% → $27Initiates → BuyGet Alert
02/10/2023GNSSBuy Now
Genasys
$2.00250%$6 → $7MaintainsOutperformGet Alert
02/01/2023TSHABuy Now
Taysha Gene Therapies
$3.00-49.92%$14 → $1.5DowngradeBuy → HoldGet Alert
01/11/2023ALBOBuy Now
Albireo Pharma
——$49 → $42DowngradeBuy → HoldGet Alert
01/09/2023CVACBuy Now
CureVac
$3.37——UpgradeHold → BuyGet Alert
12/08/2022LUMOBuy Now
Lumos Pharma
$2.60169.23%$17 → $7DowngradeBuy → HoldGet Alert
11/15/2022LUMOBuy Now
Lumos Pharma
$2.60169.23% → $7DowngradeBuy → HoldGet Alert
11/14/2022PRMEBuy Now
Prime Medicine
$7.68225.52% → $25Initiates → BuyGet Alert
09/22/2022NCNABuy Now
NuCana
$3.63-17.36%$525 → $75MaintainsBuyGet Alert
08/22/2022BPMCBuy Now
Blueprint Medicines
$103.92-19.17%$78 → $84MaintainsBuyGet Alert
06/01/2022BPMCBuy Now
Blueprint Medicines
$103.92-24.95%$88 → $78UpgradeHold → BuyGet Alert
05/24/2022UTHRBuy Now
United Therapeutics
$276.58-11.42%$223 → $245MaintainsBuyGet Alert

Recent Analyst Stock Rating News

Deep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
3 Keros Analysts On Why Biopharma Is A Compelling Investment Opportunity
Keros Therapeutics Inc (NASDAQ: KROS), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal disorders,
Jefferies Downgrades La Jolla On Weak Forecast For Blood Pressure Drug
Analysts See Potential In The NuCana Pipeline
Array BioPharma And Others Shine At The ESMO 2017 Congress
Amgen Follows Up Positive Clinical News With Earnings Beat; Jefferies Sees 24% Upside
Why Spinraza Is The Only Exciting Thing About Ionis Pharmaceuticals
Array BioPharma Marches Higher On Phase 3 Columbus Success
Jefferies Downgrades Tesaro Following 108% Stock Move
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free